Topical bFGF improves secondary lymphedema through lymphangiogenesis in a rat tail model

Plastic and Reconstructive Surgery

Volumn 2, Issue 8, 2014, Pages

  Onishi, Tetsuro ^a   Nishizuka, Takanobu ^a   Kurahashi, Toshikazu ^a   Arai, Tetsuya ^a   Iwatsuki, Katsuyuki ^a   Yamamoto, Michiro ^a   Hirata, Hitoshi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84905294257     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/GOX.0000000000000154     Document Type: Article

References (56)

1. Witte MH, Bernas MJ, Martin CP, et al. Lymphangiogenesis and lymphangiodysplasia: from molecular to clinical lymphology. Microsc Res Tech. 2001;55:122-145.
2. Oliver G, Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev. 2002;16:773-783.
3. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005;438:946-953.
4. Baluk P, Tammela T, Ator E, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest. 2005;115:247-257.
5. Harvey NL, Srinivasan RS, Dillard ME, et al. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat Genet. 2005;37:1072-1081.
6. Ji RC. Characteristics of lymphatic endothelial cells in physiological and pathological conditions. Histol Histopathol. 2005;20:155-175.
7. Browse NL. The diagnosis and management of primary lymphedema. J Vasc Surg. 1986;3:181-184.
8. de Almeida AB, Freedman DO. Epidemiology and immunopathology of bancroftian filariasis. Microbes Infect. 1999;1:1015-1022.
9. Rockson SG. Lymphedema. Curr Treat Options Cardiovasc Med. 2006;8:129-136.
10. Petrek JA, Senie RT, Peters M, et al. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001;92:1368-1377.
11. Cormier JN, Rourke L, Crosby M, et al. The surgical treatment of lymphedema: a systematic review of the contemporary literature (2004-2010). Ann Surg Oncol. 2012;19:642-651.
12. Szuba A, Rockson SG. Lymphedema: classification, diagnosis and therapy. Vasc Med. 1998;3:145-156.
13. Zampell JC, Yan A, Avraham T, et al. Temporal and spatial patterns of endogenous danger signal expression after wound healing and in response to lymphedema. Am J Physiol Cell Physiol. 2011;300:C1107-C1121.
14. Zampell JC, Elhadad S, Avraham T, et al. Toll-like receptor deficiency worsens inflammation and lymphedema after lymphatic injury. Am J Physiol Cell Physiol. 2012;302: C709-C719.
15. Kluwe J, Mencin A, Schwabe RF. Toll-like receptors, wound healing, and carcinogenesis. J Mol Med (Berl). 2009;87:125-138.
16. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004;5:74-80.
17. Yoon YS, Murayama T, Gravereaux E, et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest. 2003;111:717-725.
18. Cueni LN, Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol. 2006;126:2167-2177.
19. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell. 2010;140:460-476.
20. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040-1050.
21. Chang LK, Garcia-Cardeña G, Farnebo F, et al. Dosedependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A. 2004;101:11658-11663.
22. Morisada T, Oike Y, Yamada Y, et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood. 2005;105:4649-4656.
23. Cao R, Björndahl MA, Gallego MI, et al. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood. 2006;107:3531-3536.
24. Jin D, Harada K, Ohnishi S, et al. Adrenomedullin induces lymphangiogenesis and ameliorates secondary lymphoedema. Cardiovasc Res. 2008;80:339-345.
25. Haiko P, Makinen T, Keskitalo S, et al. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol Cell Biol. 2008;28:4843-4850.
26. Jiang D, Hu Y, Ling S. Expression of VEGF-C in rat cornea after alkali injury. J Huazhong Univ Sci Technolog Med Sci. 2004;24:483-485.
27. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312:549-560.
28. Mäkinen T, Norrmén C, Petrova TV. Molecular mechanisms of lymphatic vascular development. Cell Mol Life Sci. 2007;64:1915-1929.
29. Lohela M, Bry M, Tammela T, et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009;21:154-165.
30. Szuba A, Skobe M, Karkkainen MJ, et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J. 2002;16:1985-1987.
31. Tammela T, Saaristo A, Holopainen T, et al. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med. 2007;13:1458-1466.
32. Liu NF, He QL. The regulatory effects of cytokines on lymphatic angiogenesis. Lymphology. 1997;30:3-12.
33. Pepper MS, Wasi S, Ferrara N, et al. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells. Exp Cell Res. 1994;210:298-305.
34. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med. 2002;8:483-489.
35. Kubo H, Cao R, Brakenhielm E, et al. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A. 2002;99:8868-8873.
36. Ishibashi Y, Niimura M, Nishikawa T, et al. Investigation on clinical usefulness of recombinant human type bFGF (KCB-1) toward various pressure ulcer. J Clin Ther Med. 1993;9:2553-2570.
37. Ishibashi Y, Soeda S, Ohura T, et al. Evaluation of effect of recombinant human type bFGF (KCB-1) on pressure ulcer-The Phase III Clinical Trial Using Combination Drug of White Sugar/Povidone Iodine as Control Drug. J Clin Ther Med. 1996;12:2159-2182.
38. Soeda S, Ohura T, Shioya N, Tsukada S. Investigation on usefulness of bFGF (KCB-1) toward various pressure ulcer-The Early Phase II Clinical Trial Using 0.05% Solution. Jpn J Clin Exp Med. 1993;70:2660-2674.
39. Slavin SA, Van den Abbeele AD, Losken A, et al. Return of lymphatic function after flap transfer for acute lymphedema. Ann Surg. 1999;229:421-427.
40. Saito Y, Nakagami H, Morishita R, et al. Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via promotion of lymphangiogenesis. Circulation. 2006;114:1177-1184.
41. Okumura M, Okuda T, Nakamura T, et al. Acceleration of wound healing in diabetic mice by basic fibroblast growth factor. Biol Pharm Bull. 1996;19:530-535.
42. Serizawa F, Ito K, Matsubara M, et al. Extracorporeal shock wave therapy induces therapeutic lymphangiogenesis in a rat model of secondary lymphoedema. Eur J Vasc Endovasc Surg. 2011;42:254-260.
43. Ko DS, Lerner R, Klose G, et al. Effective treatment of lymphedema of the extremities. Arch Surg. 1998;133:452-458.
44. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290-298.
45. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev. 2002;82:673-700.
46. Mäkinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7:199-205.
47. Ancukiewicz M, Russell TA, Otoole J, et al. Standardized method for quantification of developing lymphedema in patients treated for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:1436-1443.
48. Tan Y. Basic fibroblast growth factor-mediated lymphangiogenesis of lymphatic endothelial cells isolated from dog thoracic ducts: effects of heparin. Jpn J Physiol. 1998;48:133-141.
49. Shin JW, Min M, Larrieu-Lahargue F, et al. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell. 2006;17:576-584.
50. Dailey L, Ambrosetti D, Mansukhani A, et al. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 2005;16:233-247.
51. Sharma R, Wang W, Rasmussen JC, et al. Quantitative imaging of lymph function. Am J Physiol Heart Circ Physiol. 2007;292:H3109-H3118.
52. Kwon S, Sevick-Muraca EM. Noninvasive quantitative imaging of lymph function in mice. Lymphat Res Biol. 2007;5:219-231.
53. Sharma R, Wendt JA, Rasmussen JC, et al. New horizons for imaging lymphatic function. Ann N Y Acad Sci. 2008;1131:13-36.
54. Rasmussen JC, Tan IC, Marshall MV, et al. Lymphatic imaging in humans with near-infrared fluorescence. Curr Opin Biotechnol. 2009;20:74-82.
55. Stacker SA, Achen MG, Jussila L, et al. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2:573-583.
56. Tsunoda S, Nakamura T, Sakurai H, et al. Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. Cancer Sci. 2007;98:541-548.